London, United Kingdom — A malaria vaccine developed by Britain's Oxford University is to be used in Ghana, the first time it has received regulatory clearance anywhere in the world. 'The vaccine has been approved for use in children aged 5-36 months, the age group at highest risk of death from malaria,' the university said in a statement. 'It is hoped that this first crucial step will enable the vaccine to help Ghanaian and African children to effectively combat malaria,' it added. Professor Adrian Hill, chief investigator of the R21/Matrix-M vaccine program and director of the university's Jenner Institute, said it marked the 'culmination of 30 years of malaria vaccine research at Oxford with the design and provision of a high efficacy vaccine that can be supplied at adequate scale to the countries who need it most'.
https://newsinfo.inquirer.net/1755772/malaria-vaccine-gets-green-light-for-use-in-ghana#inquirer